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Abstract: A 43-year-old woman with chronic back pain found relief by taking carisoprodol, 
a centrally acting skeletal muscle relaxant. She had acquired large amounts of the prescription 
medication through the Internet and was taking approximately three hundred 350 mg tablets 
each week, at times up to ﬁ  fty tablets per day. She then abruptly stopped the medication and 
presented to the emergency room one week later with waxing and waning attention, confusion, 
disorientation and visual hallucinations. Oral lorazepam was dosed according to a protocol 
employing the Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA). Her symp-
toms of delirium resolved rapidly and she was discharged home on day three. A review of the 
literature did not show any other reports of carisoprodol withdrawal induced delirium. Such 
withdrawal symptoms could be expected as the mechanism of action of carisoprodol is similar 
to that of hypnotic sedatives. Its availability and ease with which it can be acquired through the 
Internet puts it at great risk for a drug of abuse.
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Introduction
Carisoprodol is a skeletal muscle relaxant that exerts its effect via sedation of the 
central nervous system rather than through direct muscle relaxation (Littrell et al 
1993). Animal studies have demonstrated that carisoprodol blocks interneurons and 
depresses transmission of polysynaptic neurons in the spinal cord and descending 
reticular system of the brain. While its exact mechanism of action is unknown, it is 
pharmacologically similar to barbiturates and thought to have an indirect agonist effect 
on the same GABA-A receptor site to which barbiturates bind (Littrell et al 1993; 
Rohatgi et al 2005). A case study (Heacock and Bauer 2004) found that an individual 
taking high doses of carisoprodol had the highest stage of barbiturate tolerance during 
a pentobarbital challenge test. Furthermore, Flumazenil, a competitive antagonist of the 
GABA-A receptor site for benzodiazepines and other drugs including pentobarbital, 
has been shown to be an effective antidote for carisoprodol intoxication (Del Castillo 
and Nelson 1960; Hu and Ticku 1994; Roberge et al 2000).
With carisoprodol’s cross tolerance to barbiturates, one would expect to see similar 
withdrawal symptoms. Indeed, there have been many reports of anxiety, insomnia, 
tremors and hallucinations upon abrupt discontinuation of carisoprodol (Littrell et al 
1993; Reeves et al 2004). In other cases, patients withdrawing from carisoprodol 
reported palpitations, diaphoresis, chills, stomach cramps, headache, backpain, 
myalgias, arthralgias, diarrhea, severe psychomotor agitation, feelings of deperson-
alization, anxiety with suicidal ideation, and disorientation (Luehr et al 1990; Reeves 
and Parker 2003; Rohatgi et al 2005). Many of the above symptoms are considered 
to be characteristic of withdrawal from sedative-, hypnotic-, or anxiolytic- substances 
according to the DSM IV-TR. This class of substances include benzodiazepines, 
benzodiazepine-like drugs (eg, zolpidem), carbamates, barbiturates, barbiturate-like Neuropsychiatric Disease and Treatment 2007:3(5) 680
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hypnotics (eg, methaqualone), and some prescription sleep-
ing medications (eg, chloral hydrate and paraldehyde).
The DSM IV-TR identifies delirium as a possible 
symptom of withdrawal from sedative-, hypnotic- or 
anxiolytic- substances. Despite the similarities between this 
class of drugs and carisoprodol, there has yet to be a case 
report of delirium during carisoprodol withdrawal. Our case 
study is the ﬁ  rst to describe such a case.
Case report
A 43-year-old woman with no previous psychiatric history 
or history of substance abuse was brought to the emergency 
room by her family after seven days of worsening insomnia, 
confusion, and hallucinations.
One and a half years prior to presentation, the patient 
fell into a ditch. She experienced acute low back pain which 
developed into chronic back pain. During the six months fol-
lowing her accident, the patient tried several medications and 
therapies to alleviate her persistent back pain but found that 
only carisoprodol gave her relief. When her medical insur-
ance was terminated six months after her accident, she began 
ordering carisoprodol from Internet sites. Over the following 
year, she ordered increasing quantities from the Internet due 
to her tolerance. By the time the patient self-discontinued 
the medication at seven days prior to presentation, she had 
been taking approximately three hundred 350 mg tablets each 
week, at times up to ﬁ  fty tablets per day. Thus, she was con-
suming over ten times the indicated dosage of carisoprodol 
for acute musculoskeletal pain, which is one 350 mg tablet 
three to four times a day (DiGregorio and Barbieri 1996).
Seven days prior to presentation, the patient stopped 
taking all carisoprodol because she was “sick of taking 
medication that [she] knew was bad for [her.]” Shortly there-
after, her family reports that she began to behave bizarrely 
and appeared increasingly confused. She slept two to three 
hours each night and her appetite decreased markedly. The 
patient was anxious and had pressured speech, psychomotor 
agitation and a ﬁ  ne bilateral hand tremor. She also expe-
rienced auditory and visual hallucinations such as seeing 
shadows and her ﬁ  ancé talking to her through the television. 
One night, the patient wandered over three miles from home 
and was returned by the police. During the middle of the 
night just prior to presentation, her ﬁ  ancé found her standing 
on the front porch, wet from rain, staring up into sky with 
outstretched arms.
In the emergency room, she was disoriented to date, place 
and purpose with waxing and waning attention. She talked 
nonsensically of people walking by her room and surrounding 
her. She appeared to have no insight into these reported visual 
hallucinations. She was tachycardic at 109 beats per minute. 
Otherwise her vital signs were all within normal range. A 
neurological exam revealed postural and action tremors, but 
was otherwise normal. The only abnormal laboratory data 
were a leukocytosis of 13.1 × 103/ul white blood cells with 
9.89 × 103/mm3 neutrophils, mildly low carbon dioxide of 
19 mEq/L and slightly elevated alanine aminotransferase of 
68 U/L. Her urine toxicology screen and blood alcohol level 
were negative.
The patient was given oral lorazepam 2 mg and admit-
ted to the psychiatric unit. She was placed on a Clinical 
Institute Withdrawal Assessment of Alcohol Scale (CIWA) 
protocol. Oral lorazepam 2 mg was given for scores over 
ten. The ﬁ  rst CIWA score was fourteen triggering a second 
dose of oral lorazepam 2 mg. Subsequent CIWA scores 
were all below ten. A computed tomography head scan did 
not show evidence of acute hemorrhage, swelling, white 
matter changes, or mass lesion. The CIWA assessments were 
discontinued after the patient fell asleep.
By the morning after admission, the patient’s sensorium 
largely cleared and she remembered some of her thoughts 
while she had been delirious. She was oriented, attentive, with 
logical, reality-based thoughts. She denied hallucinations, 
and only endorsed some anxiety. Her vital signs were within 
normal limits and repeated CIWA scores were consistently 
less than three. She reported her back pain as better than it had 
been in a long while. She took two doses of 1 mg lorazepam 
in the afternoon and at bedtime for anxiety. On day three, 
the patient was discharged home, appearing to have fully 
recovered from her symptoms.
Discussion
The onset of delirium seen after abruptly stopping large daily 
doses of carisoprodol suggests that her symptoms were due 
to withdrawal from carisoprodol. Previous case studies have 
highlighted the role of meprobamate, a metabolite of cariso-
prodol, in the production of withdrawal symptoms (Reeves 
and Parker 2003). Meprobamate is a carbamate  derivative 
and belongs to the class of sedative-, hypnotic-, or anxio-
lytic- medication. The use of meprobamate has declined with 
increasing use of benzodiazepines. While carisoprodol has a 
half life of only 2.5 hours, meprobamate has a half life of 11.3 
hours or up to 48 hours with chronic use (Meyer and Straughn 
1977). According to meprobamate’s product circular, the 
onset of withdrawal occurs usually within 12–48 hours 
after discontinuation of meprobamate; symptoms usually 
cease within the next 12–48 hours. The patient of this case Neuropsychiatric Disease and Treatment 2007:3(5) 681
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experienced the onset of symptoms within the time frame 
suggested by the product circular, but symptoms persisted 
much longer than the indicated 48 hours, lasting 7 days and 
into the second day of admission. Although withdrawal 
delirium is a known consequence of the abrupt discontinu-
ation of sedative-, hypnotic-, or anxiolytic- substances, this 
case is the ﬁ  rst to report symptoms of delirium as component 
of withdrawal from carisoprodol.
The case highlights carisoprodol’s potential for depen-
dence. While the DEA is still debating whether to classify 
carisoprodol as a schedule IV drug, at least fourteen states 
have made it a schedule IV drug, including Alabama 
(1998), Nevada (2005), Arizona (2003), Georgia, Hawaii, 
Kentucky, Massachusetts, New Mexico and Oklahoma. 
Carisoprodol’s status as a non-scheduled drug belies its 
potential for abuse. Carisoprodol’s metabolite, meprobam-
ate is considered to have greater abuse potential than the 
benzodiazepines. In addition, meprobamate is classiﬁ  ed as 
a schedule IV drug.
This case also illustrates the ease with which carisopro-
dol can be obtained on the Internet. Since 1999, Internet 
companies have provided a stable supply of prescription 
medications to US customers – many of which do not require 
a visit to a physician in order to obtain a prescription but 
rather an online consultation which consists of an anonymous 
questionnaire (Forman, Woody, et al 2006). Most foreign 
web sites do not require prescriptions or an online consulta-
tion (Bloom and Iannacone 1999). These no-prescription 
websites (NPWs) generally focus on selling opioids (For-
man, Marlowe et al 2006) although many drugs of abuse 
are available including sedatives and stimulants. Prior to 
1990, a person may have had to travel to a foreign country 
to obtain medications illegally or “doctor shop” to obtain 
high quantities of medications. Today, a patient would only 
need access to the Internet and monetary resources to pay for 
the medication. With the search engines Google or Yahoo, 
several web sites that sell carisoprodol without a prescrip-
tion can easily be found. For example, searching with the 
keywords “carisoprodol no prescription” in the Yahoo search 
engine reveals nine links to suppliers claiming they will sell 
carisoprodol without a prescription.
One on-line seller site explains that their online question-
naire provides them with the information needed to grant 
a prescription – the questionnaire being a tool used by a 
licensed US doctor who writes the prescription. One study 
looked at 46 sites all of which failed to reveal the associated 
physician’s name or location (Bloom and Iannacone 1999). 
The conﬂ  ict of interest is apparent with a doctor providing 
both the prescription and reaping proﬁ  ts from the sale of the 
medication he or she prescribed.
A danger to receiving drugs via the Internet is the pos-
sibility of obtaining counterfeit or substandard medications. 
A customs lab analysis by the General Accountability Ofﬁ  ce 
and FDA showed that out of 180 drug samples seized, 
67% were either never approved by the FDA or had been 
withdrawn from the U.S. market for safety reasons, 5% con-
tained no active ingredients and 28% contained controlled 
substances prohibited from importation (Spake 2004). 
Counterfeit and substandard drugs are a huge industry with 
over $32 billion annual sales globally. With the Internet, 
it is unknown where medications are obtained. The FDA 
estimates that up to 25% of the medicines in developing 
countries are poor or substandard. In an FDA “blitz” where 
they examined 1,153 imported drugs, 99% contained unap-
proved drugs – many of which could pose safety problems 
(FDA 2003). The WHO database showed in 1999 that 77% 
of substandard medicines coming into the United States were 
from developing countries and that 60% of these medicines 
were missing the active ingredient (WHO 2003).
In general, the availability of NPWs increases the risks 
of drug abuse and diversion. Were it not for NPWs, the 
patient in our case study may not have had access to such a 
large quantity of carisoprodol and thus could have avoided 
her subsequent hospitalization. These authors believe that 
carisoprodol, a drug with abuse potential that can be acquired 
relatively easily, should be considered a scheduled drug to 
restrict its potential for harm.
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